Successful treatment pure red cell aplasia after ABO major mismatched allogeneic hematopoietic stem cell transplantation with avatrombopag and low dose rituximab.
Junjie CaoShaoyan LuDanjie LuoRenzhi PeiYing LuDong ChenXiaohong DuShuangyue LiPublished in: Transfusion (2024)
Low-dose rituximab and avatrombopag may be an effective treatment for patients with PRCA after major ABO-incompatible allo-HSCT. The patients should be treated at least 90 days post transplantation if conventional erythropoietin therapy fails.
Keyphrases
- low dose
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- newly diagnosed
- diffuse large b cell lymphoma
- high dose
- cell therapy
- acute myeloid leukemia
- ejection fraction
- acute lymphoblastic leukemia
- chronic kidney disease
- single cell
- prognostic factors
- peritoneal dialysis
- hodgkin lymphoma
- mesenchymal stem cells